PHILADELPHIA, April 11, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Century Therapeutics, Inc. is conducting ...
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% ...
Hosted on MSN
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs.
Eni says it has confirmed the extension of a play akin to its Zohr gas discovery off Egypt after confirming it has made a "promising" find off Cyprus. The Italian major remained coy, however, on key ...
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results